Safety Alerts & Recalls

What does this mean?

If you are currently receiving Avastin as treatment for metastatic breast cancer, please speak to your oncologist about this new FDA action. Your oncologist can review your treatment options with you and also use their medical judgment when deciding whether you should continue treatment with Avastin or consider other therapeutic options.

If you have other questions or concerns about Avastin, please follow up with your oncologist or other healthcare professional treating your cancer.

FDA Begins Process To Remove Breast Cancer Indication From Avastin Prescribing Information Label

The U.S. Food and Drug Administration (FDA) announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use. After reviewing of all available data relating to the use of Avastin to treat metastatic breast cancer, the FDA has determined that the risks of the drug outweigh the benefits for this use.

Avastin is also approved for treatment of advanced colon, lung, kidney, and brain cancers. Today's action does not affect the use of Avastin for these types of cancers.

To view the FDA webpage titled "Question and Answers about Avastin", please visit

more information here

For more information, please visit: more information here

Source: FDA
Publication Date: 2010-12-16
Last Updated: 2010-12-16

Visit the medication page for the following drugs:

Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.